

21 **ABSTRACT**

22 Serological testing for SARS-CoV-2 antibodies provides important research and diagnostic
23 information relating to COVID-19 immune response and surveillance. A major challenge
24 when addressing protection post- infection or vaccination is the difficulty of specimen
25 collection from infants and children. Dried blood spots (DBS) collected by finger prick or heel
26 prick are a minimally invasive sample collection alternative previously used to detect
27 antibodies to other viruses. In this study we evaluated DBS for the detection of SARS-CoV-2
28 antibodies on three commercially available enzyme (EIA) and chemiluminescent (CLIA)
29 immunoassays by analysing paired DBS and serum samples collected from 54 subjects. We
30 demonstrate that testing of DBS samples was highly sensitive and specific, and quantitative
31 results strongly correlated with those of paired serum. These results suggest that DBS
32 derived blood is a viable alternative to plasma or serum for use in EIAs and CLIAs, and has
33 particular utility as a minimally invasive collection tool for COVID-19 serological testing of
34 infants and children.


35

36 Serological methods for SARS-CoV-2 antibody detection are routinely performed on plasma
37 or serum from peripherally collected venous blood. This can be inconvenient and often
38 unacceptable to children. Dried blood spots (DBS) collected by finger prick or heel prick are
39 a minimally-invasive alternative previously used to detect antibodies against Epstein-Barr,
40 HIV, Hepatitis, Rubella and other viruses (1). Evaluation of DBS for the detection of SARS-
41 CoV-2 antibodies on commercially available enzyme (EIA) and chemiluminescent (CLIA)
42 immunoassays was performed by analysing paired DBS and serum samples from 54 subjects
43 aged between 5 and 73 years.

44 Whole blood was collected from patients via venepuncture and spotted onto DBS cards
45 (Whatman 903 Protein Saver), with the remainder put into a serum tube. DBS were then
46 processed (Supplementary materials) and tested in parallel with matched sera for
47 antibodies against SARS-CoV-2 using the spike-based ARCHITECT SARS-CoV-2 IgG II
48 Quantitative Assay (Abbott Laboratories, Abbott Park, IL, USA), and the S1 spike- and
49 nucleocapsid-based Euroimmun Anti-SARS-CoV-2 ELISA (Euroimmun, Lübeck, Germany)
50 assays, following manufacturer's instructions. The ARCHITECT SARS-CoV-2 IgG II
51 Quantitative Assay records data as arbitrary units (AU), and these results were interpreted
52 as positive (≥ 50 AU/mL) and negative (< 50 AU/mL). For Euroimmun assays, the ratio of
53 sample absorbance over the calibrator (OD ratio) was used to categorise sample results as
54 positive (≥ 1.1), equivocal ($1.1 > \text{OD} \geq 0.8$), and negative (< 0.8). Samples returning an
55 equivocal result were excluded from sensitivity and specificity calculations in this analysis.
56 Sensitivity and specificity were calculated using results of parallel testing on peripherally
57 collected serum samples as the reference standard. Concordance between quantitative
58 measurements were calculated with Pearson's Correlation Coefficient.

59 For the spike-based ARCHITECT and Euroimmun assay there were no discordant results
60 between any of the 54 paired samples. On both assays DBS testing displayed 100%
61 sensitivity and 100% specificity with reference to matched serum. The correlation
62 coefficients between quantitative serum and DBS measurements were $r = 0.9662$ ($0.9421 -$
63 0.9803 , $p < 0.0001$) and $r = 0.9831$ ($0.9708 - 0.9902$, $p < 0.0001$), respectively (Figure). On a
64 subset of 46 matched samples tested on the Euroimmun nucleocapsid-based assay there
65 was one discordant result, and DBS testing exhibited 100% sensitivity. One of 5 pairs that
66 had a negative result on serum testing was positive on DBS testing. The correlation
67 coefficient between quantitative serum and DBS measurements were $r = 0.9075$ ($0.8380 -$
68 0.9480 , $p < 0.0001$).

69



70

71

72 **Figure.** Linear regression of CLIA arbitrary units per millilitre (AU/mL) or EIA optical density (OD)
73 ratios for the detection of anti-SARS-CoV-2 IgG in 54 paired dried blood spot (DBS) and serum
74 samples. Samples were run on the ARCHITECT SARS-CoV-2 IgG II Quantitative Assay (A), and the
75 Euroimmun Anti-SARS-CoV-2 ELISA S1 spike (B) and nucleocapsid assays (C). Dotted lines indicate
76 the positive/negative, negative/equivocal, and equivocal/positive cutoffs of respective assays.

77

78 The high sensitivity and specificity of DBS tests and strong quantitative relationship with
79 paired serum on the spike-based ARCHITECT CLIA and Euroimmun EIA demonstrates the
80 validity of DBS collection for the detection of SARS-CoV-2 antibodies on these assays. This is
81 the first study to validate the quantitative ARCHITECT assay for DBS testing, and the first to
82 include paediatric specimens in analysis (Supplementary materials). Our findings also
83 confirm those of recent studies in which adult DBS were validated using semi-quantitative
84 EIAs targeting the S1 spike (2-4) and nucleocapsid proteins (3-5). These data suggest DBS
85 derived blood is a viable alternative to plasma or serum collection. It has particular utility for
86 testing infants and children, and in hotel or home quarantine where sample collection is
87 performed away from clinical settings. It can reduce transmission risks to staff collecting
88 samples from infected patients, as less time needs to be spent with the child to obtain the
89 sample. Additionally, this non-invasive tool collection tool is well suited to COVID-19
90 surveillance.

91

92 **References**

93 1. Amini F, Auma E, Hsia Y, et al. Reliability of dried blood spot (DBS) cards in antibody
94 measurement: A systematic review. PLOS ONE. 2021;16(3):e0248218.

95 2. Amendola A, Bianchi S, Gori M, et al. Dried Blood Spot as an Alternative to
96 Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to Facilitate
97 COVID-19 Surveillance Among Schoolchildren. The Pediatric Infectious Disease Journal.
98 2021;40(1):e46-e7.

99 3. Weisser H, Steinhagen K, Höcker R, Borchardt-Lohölter V, Anvari Ö, Kern PM.
100 Evaluation of dried blood spots as alternative sampling material for serological detection of
101 anti-SARS-CoV-2 antibodies using established ELISAs. Clinical Chemistry and Laboratory
102 Medicine (CCLM). 2021;59(5):979-85.

103 4. Zava TT, Zava DT. Validation of dried blood spot sample modifications to two
104 commercially available COVID-19 IgG antibody immunoassays. Bioanalysis. 2021;13(1):13-
105 28.

106 5. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-
107 CoV-2 antibody detection using the Roche Elecsys[®] high throughput immunoassay. Journal
108 of clinical virology : the official publication of the Pan American Society for Clinical Virology.
109 2021;136:104739-.

110

111

112

Supplementary Material

113

Serological detection of SARS-CoV-2 IgG using a commercially available enzyme

114

immunoassays on dried blood spots collected from patients

115 Gregory J Walker, Rebecca Davis, Zin Naing, Brad McEntee, Yonghui Lu, Tatijana Denadija,

116 William D Rawlinson

117 Corresponding author: Prof William Rawlinson, Virology Research Laboratory, Level 3

118 Clinical Sciences Building, Prince of Wales Hospital, Randwick 2031, Australia.

119 E-mail: w.rawlinson@unsw.edu.au Ph: +61 2 93829188

120

121 **This file includes:**

122 Supplementary methods. Processing of dried blood spot samples

123 Table S1. Age distribution of patients sampled

124

125 **Processing of dried blood spot samples**

126 Whole blood was collected from patients via venepuncture and spotted onto Whatman 903 Protein

127 Saver DBS cards. DBS samples were then processed by methods applicable to each assay platform.

128 For the ARCHITECT SARS-CoV-2 IgG II Quantitative Assay (Abbott Laboratories, Abbott Park, IL, USA)

129 a 6mm spot was punched using a standard office hole punch and transferred to a 2 ml round bottom

130 centrifuge tube. After 300µl of 0.25% Tergitol 15-S-9 in PBS was added, the sample tube was

131 incubated on an orbital shaker at 400 rpm for 60 min, followed by a centrifugation at 10,000g for 10

132 min. Supernatant (130µL) was then transferred to a sample cup and loaded onto ARCHITECT i2000SR

133 analyzer for testing. As the current on-market ARCHITECT SARS-CoV-2 IgG II Quantitative Assay is not

134 claimed for DBS use, a Research Use Only (RUO) assay file was installed to facilitate the DBS sample

135 measurement. The DBS method for this platform may be further modified to improve agreement

136 with quantitative serum results.

137 For the Euroimmun Anti-SARS-CoV-2 ELISA (Euroimmun, Lübeck, Germany) assays, a single 4.76mm

138 disk was punched and incubated in 250µL of ELISA buffer (kit component) for one hour at 37°C. The

139 eluted solution was then pipette mixed thoroughly and 100uL was taken forward for analysis as per

140 the manufacturer's instructions.

141 **Table S1.** Age distribution of patients sampled

Age	n=
All	54
5-12	4
13-18	4
19-40	29
41-60	12
>60	5

142